| ObjectiveTo study the cardiotoxicity monitor index of breast cancer patients who have accepted epirubicin chemotherapy and the heart protection function from Dexrazoxane.MethodsData were collected from100patients, come from The Second Xiangya Hospital and have been pathology diagnosised as breast infiltrating carcinoma after surgery. They have accepted chemotherapy and they were random divided into two groups, Dexrazoxane and no-Dexrazoxane control group,each one50patients, All of them have six period TEC adjuvant chemotherapy after operation.After selection, patients registered their general states:Name, sex, age, tumor size, lymph node shift situation, TNM stage, menstruation condition,ER PR Her-2states, past medical history and family history. Complete clinical material: Colour sonography and Myocardial Enzyme (include troponin I and high-sensitivity troponin T).Detect the change of troponin、 high-sensitivity troponin T-. left ventricular ejection fraction and non-cardiotoxicity after each chemotherapy period.Result(1) Serum high-sensitivity troponin T may rise in the early period of chemotherapy, with the increases of chemotherapy cycles, it has a remarkable increase compared with the level of pretherapy;(2) the increases of high-sensitivity troponin T of Dexrazoxane group have been obviously delayed contrast to no-dexrazoxane group, there is significant difference (P﹤0.05);(3) the change of left ventricular ejection fraction (LVEF) and troponin I after each chemotherapy period has no significant difference (P>0.05);(4)the difference of non-cardiotoxicity in two groups was not significant (P>0.05).Conclusion(1) LVEF and troponin I was not sensitive to detect epirubicin cardiotoxicity.(2) The epirubicin cardiotoxicity has a early manifestation on high-sensitivity troponin T;(3) Dexrazoxane can effectively prevent the epirubicin cardiotoxicity.(4) The use of dexrazoxane dose not increase non cardiotoxicity on epirubicin adjuvant chemotherapy. |
PDF Full Text Request